This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.
IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1
by Zacks Equity Research
IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.
Zacks.com highlights: Louisiana-Pacific, IDEXX Laboratories, SolarEdge Technologies, Curtiss-Wright and Autohome
by Zacks Equity Research
Zacks.com highlights: Louisiana-Pacific, IDEXX Laboratories, SolarEdge Technologies, Curtiss-Wright and Autohome
IDEXX Laboratories (IDXX) Beats on Q1 Revenues, View Upbeat
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q1.
Invest in These 5 Low Leverage Stocks to Earn Steady Returns
by Zacks Equity Research
With the Q1 earnings season in full swing right now, investors should target low-leveraged stocks exhibiting solid earnings growth.
Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, IDEXX Laboratories, Kohl's and Motorola Solutions
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, IDEXX Laboratories, Kohl's and Motorola Solutions
5 Top-Performing S&P 500 Stocks of Q1
by Tirthankar Chakraborty
We have highlighted five S&P 500 stocks that have dished out double-digit returns in Q1 and remained undisturbed by higher bouts of volatility
Why Should You Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX (IDXX) might gain from the commercial launch of Catalyst SDMA Test in North America. As a result, its point-of-care customers can add SDMA as an essential element to the routine chemistry panel.
IDEXX Laboratories Gains on Solid Prospects & CAG Business
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
5 of the Best Efficient Stocks for Your Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.
Second Sight (EYES) Catches Eye: Stock Jumps 12.7%
by Zacks Equity Research
Second Sight (EYES) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
IDEXX Laboratories Strong on CAG Business Amid Currency Woes
by Zacks Equity Research
IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q4.
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
by Zacks Equity Research
As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder
by Zacks Equity Research
IDEXX Laboratories (IDXX) already puts its Catalyst SDMA Test to use for hundreds of medical practices across the United States.
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter (BAX) has been gaining on the back of favorable developments in the regulatory front and product launches.
Intuitive Surgical Banks on da Vinci X, Forex Woes Remain
by Zacks Equity Research
Intuitive Surgical's (ISRG) consistent efforts to boost da Vinci X platform is a positive. However, foreign exchange movements are impacting the company's results
6 MedTech Stocks Set to Crush the Market in 2018
by Zacks Equity Research
Here we take a peek at six MedTech stocks that are expected to post stellar returns in 2018.